Abstract
Small, open-label studies show promising results for ECP in the treatment of steroid-dependent and medically-refractory Crohn's disease. However, proper randomized, sham-controlled trials have not yet been performed. Based on the proposed mechanism of action of ECP, induction of a tolerogenic T cell response, ECP should be assessed in patients with early inflammatory disease rather than those who have progressed to fibrotic or stricturing disease. Randomized, sham-controlled trials need to be performed before ECP can be incorporated into standard clinical practice for the treatment of Crohn's disease.
Original language | English |
---|---|
Pages (from-to) | 183-186 |
Number of pages | 4 |
Journal | Transfusion and Apheresis Science |
Volume | 52 |
Issue number | 2 |
Early online date | 15 Feb 2015 |
DOIs | |
Publication status | Published - Apr 2015 |
Keywords
- Blood Component Removal
- Clinical Trials as Topic
- Crohn Disease
- Humans
- Immunosuppressive Agents
- Inflammation
- Photopheresis
- Research Design
- Steroids
- T-Lymphocytes
- Treatment Outcome
- Journal Article
- Review